Metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations
申请人:The University of Chicago
公开号:US10647733B2
公开(公告)日:2020-05-12
Metal-organic framework (MOFs) compositions based on nitrogen donor-based organic bridging ligands, including ligands based on 1,3-diketimine (NacNac), bipyridines and salicylaldimine, were synthesized and then post-synthetically metalated with metal precursors, such as complexes of first row transition metals. Metal complexes of the organic bridging ligands could also be directly incorporated into the MOFs. The MOFs provide a versatile family of recyclable and reusable single-site solid catalysts for catalyzing a variety of asymmetric organic transformations. The solid catalysts can also be integrated into a flow reactor or a supercritical fluid reactor.
Amino Acid‐Functionalized Metal‐Organic Frameworks for Asymmetric Base–Metal Catalysis
作者:Rajashree Newar、Naved Akhtar、Neha Antil、Ajay Kumar、Sakshi Shukla、Wahida Begum、Kuntal Manna
DOI:10.1002/anie.202100643
日期:2021.5.3
We report a strategy to develop heterogeneous single‐site enantioselective catalysts based on naturally occurring aminoacids and earth‐abundant metals for eco‐friendly asymmetric catalysis. The grafting of aminoacids within the pores of a metal‐organic framework (MOF), followed by post‐synthetic metalation with iron precursor, affords highly active and enantioselective (>99 % ee for 10 examples)
[EN] NANOSCALE CARRIERS FOR THE DELIVERY OR CO-DELIVERY OF CHEMOTHERAPEUTICS, NUCLEIC ACIDS AND PHOTOSENSITIZERS<br/>[FR] VECTEURS NANOMÉTRIQUES POUR L'ADMINISTRATION OU LA CO-ADMINISTRATION D'AGENTS CHIMIOTHÉRAPEUTIQUES, D'ACIDES NUCLÉIQUES ET DE PHOTOSENSIBILISATEURS
申请人:UNIV CHICAGO
公开号:WO2015069926A1
公开(公告)日:2015-05-14
Nanoscale coordination polymer nanoparticles for the co-delivery of multiple therapeutic agents are described. The multiple therapeutic agents can include a combination of different chemotherapeutic agents, a combination of one or more chemotherapeutic agents and one or more nucleic acids, such as small interfering RNA (siRNA) or microRNA, a combination of one or more chemotherapeutic agents and a photosensitizer (i.e., for use in photodynamic therapy), or a plurality of different siRNAs. Pharmaceutical formulations including the nanoparticles, methods of using the nanoparticles to treat cancer, and methods of making the nanoparticles are also described.